Company
Headquarters: Weybridge, United Kingdom
Founded: 18 July 2022
CEO: Brian McNamara
£29.50 Billion
GBP as of July 1, 2024
US$37.32 Billion
Haleon plc, headquartered in Brentford, UK, specializes in the R&D, manufacture, and sale of consumer healthcare products across various regions. Their offerings encompass therapeutic oral health, pain relief, respiratory, digestive products, and vitamins and supplements. Key brands include Panadol, Voltaren, Advil, Sensodyne, and Centrum.
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Haleon plc has the following listings and related stock indices.
Stock: LSE: HLN wb_incandescent
Stock: NYSE: HLN wb_incandescent
Oral hygiene and medicines, nutritional products, over-the-counter medicines